Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target increased by equities research analysts at Leerink Partners from $12.00 to $15.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. Leerink Partners’ target price suggests a potential downside of 14.97% from [...]
Leerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00
